Rose Sharon Shabet is 10% Owner at Urovant Sciences Ltd. (UROV). They have made 7 open-market trades across 5 companies since 2019, most recently 2023-09-19.
CIK 0001711393
6 open-market purchases totalling $119.0M since 2019, against 1 sale. Across 6 scored buys the stock is up 11.2% at ninety days, and 6.4 points ahead of the S&P over the same stretch.
6 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 50% | 83% | 67% |
| Avg Move | +0.7% | +14.7% | +11.2% |
| Alpha | +0.8% | +12.1% | +6.4% |
| Scored | 6 | 6 | 6 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| RYZB | BUY | 2023-09-19 | 2023-09-21 | $18.00 | $25.0M | +0.8% | -5.5% | +36.0% |
| FDMT | BUY | 2023-05-09 | 2023-05-11 | $16.00 | $13.6M | +2.1% | +30.3% | -3.2% |
| FIGS | SELL | 2021-09-02 | 2021-09-03 | $46.78 | $18.7M | -4.7% | -18.7% | -27.6% |
| BBIO | BUY | 2019-06-27 | 2019-06-28 | $17.00 | $80.0M | +8.6% | +4.6% | -22.5% |
| UROV | BUY | 2019-06-14 | 2019-06-14 | $7.91 | $57K | -2.4% | +19.6% | +18.9% |
| UROV | BUY | 2019-06-13 | 2019-06-14 | $7.95 | $59K | -2.4% | +19.6% | +18.9% |
| UROV | BUY | 2019-06-12 | 2019-06-14 | $8.30 | $62K | -2.4% | +19.6% | +18.9% |
| UROV | BUY | 2019-06-12 | 2019-06-14 | $8.06 | $177K | -2.4% | +19.6% | +18.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.